Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir

被引：46

作者：

Hussain, M

Fung, S

Libbrecht, E

Sablon, E

Cursaro, C

Andreone, P

Lok, ASF

机构：

[1] Univ Michigan, Ctr Med, Div Gastroenterol, Ann Arbor, MI 48109 USA

[2] Innogenet NV, Ghent, Belgium

[3] Univ Bologna, Dipartimento Med Interna Cardioangiol & Epatol, Bologna, Italy

来源：

JOURNAL OF CLINICAL MICROBIOLOGY | 2006年 / 44卷 / 03期

关键词：

D O I：

10.1128/JCM.44.3.1094-1097.2006

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The INNO-LiPA HBV DR Q assay is designed to detect hepatitis B virus mutations conveying resistance to lamivudine and adefovir. Our study confirms that this assay can simultaneously detect the presence of lamivudine and adefovir resistance mutations in clinical samples, has a high degree of concordance with sequencing, and can detect mutants earlier.

引用

页码：1094 / 1097

页数：4

共 7 条

[1] Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion [J].

Chan, HLY ;

Hussain, M ;

Lok, ASF .

HEPATOLOGY, 1999, 29 (03) :976-984

[2] Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis [J].

Ghany, MG ;

Ayola, B ;

Villamil, FG ;

Gish, RG ;

Rojter, S ;

Vierling, JM ;

Lok, ASF .

HEPATOLOGY, 1998, 27 (01) :213-222

[3] Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants [J].

Hussain, M ;

Chu, CJ ;

Sablon, E ;

Lok, ASF .

JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (08) :3699-3705

[4] Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine [J].

Lo, CM ;

Liu, CL ;

Lau, GK ;

Chan, SC ;

Ng, IO ;

Fan, ST .

LIVER TRANSPLANTATION, 2005, 11 (07) :807-813

[5] Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: Evaluation of performance of INNO-LiPA HBV DR assay [J].

Lok, ASF ;

Zoulim, F ;

Locarnini, S ;

Mangia, A ;

Niro, G ;

Decraemer, H ;

Maertens, G ;

Hulstaert, F ;

De Vreese, K ;

Sablon, E .

JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (10) :3729-3734

[6] Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants [J].

Marzano, A ;

Lampertico, P ;

Mazzaferro, V ;

Carenzi, S ;

Vigano, M ;

Romito, R ;

Pulvirenti, A ;

Franchello, A ;

Colombo, M ;

Salizzoni, M ;

Rizzetto, M .

LIVER TRANSPLANTATION, 2005, 11 (05) :532-538

[7] Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients [J].

Schiff, ER ;

Lai, CL ;

Hadziyannis, S ;

Neuhaus, P ;

Terrault, N ;

Colombo, M ;

Tillmann, HL ;

Samuel, D ;

Zeuzem, S ;

Lilly, L ;

Rendina, M ;

Villeneuve, JP ;

Lama, N ;

James, C ;

Wulfsohn, MS ;

Namini, H ;

Westland, C ;

Xiong, S ;

Choy, GS ;

Van Doren, S ;

Fry, J ;

Brosgart, CL ;

Shakil, AO ;

Fung, J ;

Alberti, A ;

Lok, A ;

Picciotto, A ;

Torre, F ;

Riely, C ;

Trepo, C ;

Poizollan, T ;

Botta-Fridlund, D ;

Gerolami, R ;

Douglas, D ;

Ranjan, D ;

Faust, D ;

Trojan, J ;

Gane, E ;

Villa, E ;

Boarino, V ;

Sokal, E ;

Starel, P ;

Bonino, F ;

Brunetto, M ;

Gordon, F ;

Pratt, J ;

Berr, F ;

Schiefke, I ;

McCaughan, G ;

Strasser, S .

HEPATOLOGY, 2003, 38 (06) :1419-1427

← 1 →